Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Bispecific antibody therapy in multiple myeloma is impaired by tumor-associated macrophages through dual immunosuppressive and antigen-dependent mechanisms

Vivien Reinecke, Kereshmeh Tasbihi, Maike Büttner-Herold, Johannes Berges, Christopher Lischer, Katrin Bitterer, Simon Voelkl, Frederik Graw, Pascal Lukas, Matthias Peipp, Leo Rasche, Dimitrios Mougiakakos, Andreas Mackensen, Heiko Bruns

Blood (2025) 146 (Supplement 1): 5711.

https://doi.org/10.1182/blood-2025-5711

Published: 2025

Journal Articles

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Blood (2025) 146 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2025-1949

Published: 2025

Journal Articles

Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma

Nora Rebecca Schwingen, Fabian Müller, Melanie Hagen, Andreas Wirsching, Michael Aigner, Sascha Kretschmann, Soraya Kharboutli, Julia Scholz, Giulia Benintende, Jule Taubmann, Tobias Krickau, Nora Naumann-Bartsch, Heiko Bruns, Ricardo Grieshaber-Bouyer, Frederik Graw, Markus Metzler, Georg Schett, Andreas Mackensen, Simon Voelkl

Blood (2025) 146 (Supplement 1): 1947.

https://doi.org/10.1182/blood-2025-1947

Published: 2025

Journal Articles

Identification of CD4+ T cells targeting DM-sensitive antigens presented on mismatched HLA-DP alleles, as mediators of a selective graft-versus-leukemia effect.

Katharina Korn, Tabea Koch, Vanessa Lang, Katharina Götz, Simone Thomas, Julia Winkler, Anja Wagner, Simon Voelkl, Heiko Bruns, Lisa Denzin, Kilian Schober, Carolin Moosmann, Andreas Mackensen, Anita Kremer, Hannah Reimann

Blood (2025) 146 (Supplement 1): 4235.

https://doi.org/10.1182/blood-2025-4235

Published: 2025

Journal Articles

Late re-expansion and high-level persistence of CAR T-cells can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma

Fabian Müller, Nora Rebecca Schwingen, Anne Hartebrodt, Nicolai Meyerhoefer, Guranda Chitadze, Soraya Kharboutli, Heiko Bruns, Arif Ekici, Kerstin Schäfer-Eckart, Stefan Knop, Frederik Graw, David Blumenthal, Michael Rehli, Monika Brüggemann, Andreas Mackensen, Simon Voelkl

Blood (2025) 146 (Supplement 1): 4171.

https://doi.org/10.1182/blood-2025-4171

Published: 2025

Journal Articles

Safety and preliminary efficacy of anti-CD19 CAR T cells zorpocabtagene-autoleucel in systemic autoimmune diseases: Final analysis of the castle trial

Blood (2025) 146 (Supplement 1): 2380.

https://doi.org/10.1182/blood-2025-2380

Published: 2025

Journal Articles

Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma - a Single-Center Experience

Blood (2024) 144 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2024-207051

Published: 2024

Journal Articles

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Blood (2024) 144 (Supplement 1): 684.

https://doi.org/10.1182/blood-2024-206163

Published: 2024

Journal Articles

Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

Vivien Reinecke, Daniel Hofbauer, Jörg-Thomas Bittenbring, Christopher Lischer, Johannes Berges, Gina Nusser, Katrin Bitterer, Simon Voelkl, Dimitrios Mougiakakos, Andreas Mackensen, Heiko Bruns

Blood (2024) 144 (Supplement 1): 1153.

https://doi.org/10.1182/blood-2024-203108

Published: 2024

Journal Articles

CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

Haroon Shaikh, Cindy Flamann, Carina Matos, Hla Ali, Michael AG Kern, Marina Kreutz, Maike Buettner-Herold, Christopher Lischer, Simon Voelkl, Christian Kellner, Katrin Bitterer, Domenica Saul, Ernst Holler, Alma Zernecke, Dimitrios Mougiakakos, Andreas Beilhack, Heiko Bruns

Blood (2024) 144 (Supplement 1): 2023.

https://doi.org/10.1182/blood-2024-205870

Published: 2024

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

Blood (2023) 142 (Supplement 1): 220.

https://doi.org/10.1182/blood-2023-180547

Published: 2023

Journal Articles

CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 6871.

https://doi.org/10.1182/blood-2023-188830

Published: 2023

Journal Articles

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Blood (2022) 140 (Supplement 1): 7522–7523.

https://doi.org/10.1182/blood-2022-168874

Published: 2022

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Fabian Mueller, Simon Voelkl, Dimitrios Mougiakakos, Sebastian Boeltz, Michael Aigner, Regina Gary, Sascha Kretschmann, Soraya Kharboutli, Arnd Kleyer, David Simon, Wolf Rösler, Katharina M. Habenicht, Thomas H. Winkler, Gerhard Krönke, Georg Schett, Andreas Mackensen

Blood (2022) 140 (Supplement 1): 4562–4563.

https://doi.org/10.1182/blood-2022-165077

Published: 2022

Journal Articles

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Blood (2022) 140 (Supplement 1): 9292–9293.

https://doi.org/10.1182/blood-2022-159955

Published: 2022

Journal Articles

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Blood (2022) 140 (Supplement 1): 4549–4551.

https://doi.org/10.1182/blood-2022-167632

Published: 2022

Journal Articles

Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation

Nina Eisenhauer, Maurizio Miano, Nora Naumann-Bartsch, Joerg Leyh, Paola Terranova, Claas Hinze, Michael Aigner, Helmut Wittkowski, Heiko Bruns, Stephan Ehl, Markus Metzler, Peter Arkwright, Andreas Mackensen, Anne Rensing-Ehl, Simon Voelkl

Blood (2022) 140 (Supplement 1): 11194.

https://doi.org/10.1182/blood-2022-168550

Published: 2022

Journal Articles

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

Hannah Reimann, Anita Natalie Kremer, Viktoria Blumenberg, Katja Schmidt, Michael Aigner, Andreas Kremer, Matthias Tenbusch, Heiko Bruns, Thomas Harrer, Georg Schett, Fabian Mueller, Andreas Mackensen, Marion Subklewe, Simon Voelkl

Blood (2022) 140 (Supplement 1): 10279–10280.

https://doi.org/10.1182/blood-2022-165968

Published: 2022

Journal Articles

Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Richard Pelzl, Sabrina Kübel, Paulina Klein, Franziska Gsottberger, Kerstin Wendland, Srdjan Petkovic, Valeska Brueckl, Rebecca Baur, Simon Voelkl, Andreas Mackensen, Krystelle Nganou-Makamdop, Fabian Müller

Blood (2022) 140 (Supplement 1): 6432–6433.

https://doi.org/10.1182/blood-2022-167216

Published: 2022

Journal Articles

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Maximilian Alexander A Rohnert, Malte von Bonin, Michael Kramer, Philipp Ensel, Nadja Holtschke, Christoph Rollig, MD MSC, Martin Bornhäuser, MD, Veit Buecklein, MD, Marion Subklewe, MD, Stefan W Krause, Simon Voelkl, Tobias Berg, Michael A Rieger, Cornelia Brendel, Jörg Hoffmann, Nicole Hofmeister-Mielke, Richard F. Schlenk, Sylvie D Freeman, Uta Oelschlägel

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-138683

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Bispecific antibody therapy in multiple myeloma is impaired by tumor-associated macrophages through dual immunosuppressive and antigen-dependent mechanisms

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Distinct inflammatory and immune recovery patterns after CD19-directed CAR T-cell therapy in SLE and B-cell lymphoma

Identification of CD4+ T cells targeting DM-sensitive antigens presented on mismatched HLA-DP alleles, as mediators of a selective graft-versus-leukemia effect.

Late re-expansion and high-level persistence of CAR T-cells can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma

Safety and preliminary efficacy of anti-CD19 CAR T cells zorpocabtagene-autoleucel in systemic autoimmune diseases: Final analysis of the castle trial

Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma - a Single-Center Experience

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

CD47 Upregulation Inhibits Phagocytic Clearance of Alloreactive Donor T Cells after Allo-HCT

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only